IP Library Granted Patent US 8,980,872
Granted Patent B2
US 8,980,872 · App. 13/061,239 · Granted Mar 17, 2015

Agent for preventing and/or treating functional gastrointestinal disorder

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,872
App. No.
13/061,239
Granted
Mar 17, 2015
Kind
B2
Abstract

A method for preventing and/or treating a functional gastrointestinal disorder, comprising administering, to a subject with the functional gastrointestinal disorder, rifaximin as an effective ingredient. The functional gastroinstestinal disorder includes a functional esophageal disorder, a functional gastroduodenal disorder (e.g., a functional dyspepsia), a functional bowel disorder (e.g., a functional bloating, a functional diarrhea), a functional abdominal pain syndrome, a functional gallbladder and Sphincter of Oddi disorder, a functional anorectal disorder (e.g., a functional fecal incontinence, a functional anorectal pain, a functional defecation disorder), a functional disorder in neonates and toddlers (e.g., an infant functional diarrhea), a functional disorder in children and adolescents (e.g., a childhood functional abdominal pain, a childhood nonretentive fecal incontinence), and other diseases.

Claims (3)

1. A method for treating a functional gastrointestinal disorder, comprising administrating, to a subject with the functional gastrointestinal disorder, rifaximin as an effective ingredient, wherein the functional gastrointestinal disorder is a functional dyspepsia with a diarrhea caused by stress, and

wherein the method (a) reduces a number of stools, (b) normalizes a nature of stool, or (c) reduces a number of stools and normalizes motility of intestinal tract.

2. The method according to claim 1 , which normalizes motility of intestinal tract.

Assignments (4)
CHANGE OF ADDRESS Recorded Oct 15, 2019
From: ALFASIGMA S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 050727/0652 →
MERGER Recorded Nov 14, 2017
From: ALFA WASSERMANN S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 045061/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2015
From: ASKA PHARMACEUTICAL CO., LTD.
To: ALFA WASSERMANN S.P.A.
Reel/Frame 036533/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2011
From: TAMAOKI, SATORU; SATO, JUN; SUDO, KATSUICHI
To: ASKA PHARMACEUTICAL CO., LTD.
Reel/Frame 025872/0343 →